Skip to main content

Table 4 Unadjusted HR estimates of the treatment by marker effects

From: Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

  

RFS

OS

  

HR

95% CI

TxM (HR)

HR

95% CI

TxM (HR)

TIMP-1

Negative (n = 167; 58%)

0.642

0.377 to 1.091

1.311

0.784

0.447 to 1.376

1.667

 

Positive (n = 121; 42%)

0.478

0.247 to 0.927

(0.562 to 3.056)

0.461

0.213 to 1.002

(0.641 to 4.339)

2T Profile

Responsive (n = 183; 66.8%)

0.613

0.365 to 1.029

1.022

0.450

0.188 to 1.080

1.579

 

Non-responsive (n = 91; 33.2%)

0.582

0.277 to 1.221

(0.415 to 2.520)

0.739

0.428 to 1.277

(0.565 to 4.411)

HT Profile

Responsive (n = 181; 66.1%)

0.658

0.400 to 1.082

0.902

0.783

0.464 to 1.320

0.577

 

Non-responsive (n = 93; 33.9%)

0.531

0.235 to 1.200

(0.347 to 2.346)

0.384

0.141 to 1.046

(0.186 to 1.788)